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process include vascular smooth muscle cell (VSMC)
proliferation, extracellular matrix (ECM) deposition,
and VSMC migration along the ECM. VSMC
chemotaxis, migration directed toward a chemoat-
tractant along a gradient, is an essential component
of IH and has long been associated with growth fac-
tor stimulation. Only recently has attention been
directed to the role of the ECM in stimulating
VSMC chemotaxis and the intracellular signaling
pathways involved in this process. 
Chemotaxis is a complex process that involves
extracellular signals that activate intracellular path-
ways, resulting in the disassembly of focal adhesion
complexes, actin filament reorganization, actin-
myosin interactions, and directed migration.2 In IH,
VSMC migration can occur with and in response 
to the ECM and its constituent proteins.3
Thrombospondin-1 (TSP-1), fibronectin (Fn), and
1160
Intimal hyperplasia (IH), a multifactorial process
associated with vascular injury, is a significant cause
of graft failure after vascular surgery or balloon
angioplasty.1 The events that characterize this
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Purpose: Intimal hyperplasia (IH), a significant cause of vascular reconstructive failure,
is characterized by abnormal vascular smooth muscle cell (VSMC) migration, prolifera-
tion, and extracellular matrix (ECM) deposition. The ECM proteins, thrombospondin-
1 (TSP-1), fibronectin (Fn), and vitronectin (Vn) can induce VSMC migration; howev-
er, the cellular signaling pathways involved are not identical for each ECM protein.
Phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) are two enzymes that
have been associated with VSMC migration. We sought to elucidate the roles of these
enzymes in TSP-1-, Fn-, and Vn-stimulated VSMC migration. 
Methods: Chemotaxis assays were performed by using a modified Boyden Chamber. TSP-
1, Fn, or Vn (20 µg/mL) or serum-free media (SFM) was placed in the bottom wells of
the chamber. Quiescent bovine aortic VSMC were preincubated with LY 294002 (100
µmol/L), a PI3K inhibitor, bisindolylmaleimide I (GF 109203X, 1 µmol/L), a PKC
inhibitor, or in SFM alone for 30 minutes. VSMCs (50,000 cells per well) were then
placed in the top wells of the chamber, and the assay was conducted for 4 hours at 37°C.
Results were recorded as the number of cells migrated per five fields (400×) and ana-
lyzed by means of the paired t test, with P value less than .05 considered to be signifi-
cant (n = 3).
Results: The VSMC migration was significantly increased by TSP-1, Fn, and Vn. LY
294002 inhibited TSP-1-, Fn-, and Vn-stimulated VSMC migration (85% to 89%, P <
.05). GF 109203X inhibited only TSP-1-stimulated migration (65%, P < .05). 
Conclusion: These results suggest that TSP-1-, Fn-, and Vn-stimulated migration is at
least partially dependent on PI3K. However, only TSP-1 stimulated migration is at least
partially dependent on PKC. (J Vasc Surg 2000;31:1160-7.)
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vitronectin (Vn) are three ECM structural glycopro-
teins that are associated with VSMC migration and
increase locally in response to vascular injury and
atherosclerosis.4-9
Our laboratory reported involvement of the mito-
gen-activated protein kinase (MAPK) pathways as a
mechanism of TSP-1-induced VSMC chemotaxis.10
The MAPK pathway, extracellular signal-regulated
kinases 1/2 (ERK1/2), was shown to be activated by
TSP-1, and TSP-1-induced VSMC chemotaxis was
inhibited by the ERK1/2 inhibitor, PD98059.10
Additionally, the influence of ERK1/2 and p38 kinase
inhibition varied with the ECM chemoattractant,
TSP-1, Fn, or Vn. In particular, TSP-1-induced
chemotaxis was shown to be more sensitive to
ERK1/2 and p38 kinase inhibition.11 This finding
lead to a further interest in distinguishing the mecha-
nisms by which each of these ECM glycoproteins
induces VSMC chemotaxis.
Phosphatidylinositol 3-kinase (PI3K) and pro-
tein kinase C (PKC) are two families of proteins
associated with intracellular signal transduction
stimulated by extracellular stimuli that result in
VSMC migration.12,13 Both PI3K and PKC have
been implicated as potential activators of MAPK.14
The purpose of this study was to define further the
intracellular signaling pathways involved in TSP-1-,
Fn-, and Vn-induced VSMC chemotaxis by analyz-
ing the roles of PI3K and PKC.
METHODS
Vascular smooth muscle cell culture. Bovine
aortic VSMCs were isolated in the manner previous-
ly described and seeded in Dulbecco’s modified
Eagle’s medium (Sigma, St Louis, Mo), which con-
tained 10% fetal bovine serum and 1% antibiotics
(Gibco BRL, Gaithersburg, Md) in primary cul-
ture.15 The VSMCs were used in early passage (2 to
5) for experiments. Subconfluent monolayers of
VSMCs were quiescent (48 hours) in serum-free
medium (SFM) before each experiment.
Extracellular matrix proteins. Purified TSP-1,
derived from human platelets, was provided by Jack
Lawler, PhD (Beth Israel Deaconess Medical
Center, Boston, Mass).16 Fn and Vn, derived from
human plasma, were purchased from Sigma (St
Louis, Mo). The concentration of each ECM pro-
tein was 20 µg/mL, based on chemotaxis assay con-
centration curves for each protein, which showed
that a similar degree of chemotaxis occurs at this
concentration for each protein.11 SFM served as the
negative control chemoattractant.
Pathway inhibitors. The PI3K inhibitor, LY
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294002, which acts at the adenosine triphosphate
(ATP)-binding site of PI3K, was purchased from
Calbiochem (La Jolla, Calif). The PKC inhibitor,
bisindolylmaleimide I (GF109203X), which com-
petitively inhibits the ATP-binding site of PKC, was
purchased from Calbiochem (La Jolla, Calif). The
concentration of LY 294002, 100 µmol/L, was
established by means of concentration studies that
used 10, 50, and 100 µmol/L. At 100 µmol/L of
LY 294002, PI3K inhibition could maximally inhib-
it ECM-induced migration without affecting migra-
tion of unstimulated cells. Similarly, concentration
studies for GF 109203X were performed with 100
nmol/L, 1 µmol/L, and 5 µmol/L, which estab-
lished that at 1 µmol/L of GF 109203X, PKC inhi-
bition can maximally inhibit ECM-induced migra-
tion without affecting migration of unstimulated
cells. The inhibitors were determined to not have
toxic effects on VSMC migration by means of mor-
phologic appearance and trypan blue staining.
Chemotaxis assay. A modified Boyden 48-well
microchemotaxis chamber with a Poretics polycar-
bonate polyvinylpyrrolidone-free membrane with 8-
µm pores from Neuroprobe (Cabin John, Md) was
used for chemotaxis assays.10 Quiescent VSMCs
were isolated by means of incubation with trypsin
and concentrated in a suspension of one million cells
per milliliter SFM. One milliliter of VSMC suspen-
sion was preincubated with LY 294002 (10, 50, or
Fig 1. Chemotaxis concentration curve for LY 294002.
Preincubation of vascular smooth muscle cells with the
phosphatidylinositol 3-kinase inhibitor LY 294002 (10,
50, and 100 µmol/L) demonstrated significant inhibition
of thrombospondin-1 (TSP-1)-, fibronectin (Fn)-, and vit-
ronectin (Vn)-induced chemotaxis at 50 and 100 µmol/L.
*P < .05 and **P < .005, compared with their respective
uninhibited vascular smooth muscle cell chemotaxis
toward TSP-1, Fn, or Vn. A representative experiment is
shown.
100 µmol/L), 1 mL with GF 109203X (100
nmol/L, 1 µmol/L, or 5µmol/L), or 1 mL with
SFM for 30 minutes at room temperature. Thirty µL
of SFM or the chemoattractants TSP-1, Fn, or Vn
(20 µg/mL) was placed in the respective bottom
wells of the chamber. The membrane and gasket
were then applied, followed by the top component
of the chamber. The VSMCs (50,000 cells per well),
preincubated with their appropriate inhibitor or
SFM, were placed in the wells of the top chamber.
The modified Boyden chamber was then incubated
at 37°C, and the assay was run for 4 hours. The
membrane was then removed from the chamber,
fixed in 70% ethanol, stained in hematoxylin, and
mounted on a slide. VSMCs that settled on the top
side of the membrane were removed by using a cot-
ton swab. The VSMCs that migrated through the
pores to the undersurface of the membrane were
then counted under high power (400×) for five
fields per well.
Statistical analysis. The number of migrated
VSMCs per five fields under high power (400×) was
calculated for each experimental group. Each exper-
iment was performed in triplicate and repeated at
least three times. The data were analyzed by means
of paired t test. A P value less than .05 was consid-
ered significant.
RESULTS
Chemotaxis. A statistically significant increase in
VSMC chemotaxis was observed in response to the
ECM proteins (positive controls) TSP-1, Fn, and Vn
(20 µg/mL) versus the SFM control (P < .05; Figs
1-4). At a concentration of 20 µg/mL, the ECM
proteins were not significantly different from each
other in the degree of chemotaxis induced (P = .31,
TSP-1 vs Fn; P = .12, TSP-1 vs Vn; P = .37, Fn vs
Vn). Negative controls (SFM) indicated that the
concentrations of inhibitors used did not have any
significant effect on the baseline migratory function
of the cells.
Phosphatidylinositol 3-kinase inhibition.
Preincubation of VSMCs with the PI3K inhibitor,
LY 294002 (50 and 100 µmol/L) resulted in signif-
icant inhibition of ECM-induced VSMC chemo-
taxis, compared with each respective positive control
(P < .05 at 50 µmol/L; P < .005 at 100 µmol/L;
Fig 1). LY 294002 (100 µmol/L) inhibited TSP-1-
induced VSMC chemotaxis by 88.5% ± 5.7% (P <
.0001). LY 294002 (100 µmol/L) inhibited Fn-
induced VSMC migration by 84.9% ± 8.7% (P <
.005). The Vn-induced VSMC chemotaxis was
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Fig 2. Attenuation of vascular smooth muscle cell 
chemotaxis by phosphatidylinositol 3-kinase inhibition.
Preincubation of vascular smooth muscle cells with the phos-
phatidylinositol 3-kinase inhibitor LY 294002 (100
µmol/L) significantly attenuated vascular smooth muscle
cell chemotaxis toward thrombospondin-1 (TSP-1),
fibronectin (Fn), and vitronectin (Vn), to a level not signifi-
cantly different from vascular smooth muscle cells exposed to
serum-free media (SFM), P <.05. The chemoattractants
TSP-1, Fn, and Vn (20 µg/mL) induced a significant
increase in chemotaxis of uninhibited vascular smooth mus-
cle cells, in comparison with SFM (P < .05). LY 294002 had
no significant effect on the migration of vascular smooth
muscle cells exposed to SFM. A representative experiment is
shown. Experiments were performed in triplicate and repeat-
ed at least three times. *P < .05, compared with their respec-
tive uninhibited vascular smooth muscle cell chemotaxis
toward TSP-1, Fn, or Vn.
Fig 3. Chemotaxis concentration curve for GF 109203X.
Preincubation of vascular smooth muscle cells with the
protein kinase C inhibitor GF 109203X (100 nmol/L, 1
µmol/L, and 5 µmol/L) demonstrated significant inhibi-
tion of thrombospondin-1 (TSP-1)–induced chemotaxis at
1 and 5 µmol/L. *P < .05, compared with their respective
uninhibited vascular smooth muscle cells chemotaxis
toward TSP-1, Fn, or Vn. A representative experiment is
shown.
inhibited by 88.1% ± 11.1% (P < .0001) by LY
294002 (Table). LY 294002 (100 µmol/L) inhibit-
ed chemotaxis for TSP-1, Fn, and Vn to a degree
not significantly different from uninhibited VSMCs
exposed to SFM only (P = .17 for TSP-1; P = .25 for
Fn; P = .45 for Vn; Fig 2). The difference in LY
294002’s (100 µmol/L) degree of inhibition
among the different ECM proteins was not statisti-
cally significant (TSP vs Fn, P = .52; TSP vs Vn, P =
.94; Fn vs Vn, P = .63).
Protein kinase C inhibition. Preincubation of
VSMCs with the PKC inhibitor, GF 109203X (1
and 5 µmol/L), resulted in significant inhibition of
TSP-1-induced VSMC chemotaxis, compared with
the positive control (P < .05), but did not result in
the significant inhibition of Fn- or Vn-induced
VSMC chemotaxis (Fig 3). The TSP-1-induced
VSMC chemotaxis was inhibited 64.5% ± 12.1% (P
= .02) by GF 109203X (1 µmol/L). The Fn-
induced VSMC chemotaxis, however, was inhibited
only 23.0% ± 6.1% (P = .11). The Vn-induced
VSMC chemotaxis was inhibited 19.4% ± 8.8% (P =
.11; Table; Fig 4).
DISCUSSION
TSP-1, Fn, and Vn are multifunctional ECM gly-
coproteins that are associated with VSMC migration
and intimal plaque formation.4-9 They are classified
as acute phase proteins because of their local increase
during stress, such as tissue injury.17 However, TSP-
1 differs from Fn and Vn in the degree of increased
presence in acute pathologic states.18,19 For exam-
ple, TSP-1 is almost absent in normal arteries, is
increased acutely after arterial injury, and is
decreased in a more chronic phase.5,20,21 In con-
trast, Fn and Vn are present in the media of normal
arteries and become increased further after acute
arterial injury and intimal thickening.7,9
These three ECM proteins have some common
functional roles; they induce VSMC migration and
cellular attachment. The binding of ECM proteins
to integrin and integrin-associated receptors and the
subsequent activation of cell signaling pathways of
VSMCs are associated with VSMC chemotaxis.12
Although several forms of cell migration may be
involved in vascular pathophysiology, we focused on
chemotaxis that is directed migration of cells toward
a chemoattractant, in this case ECM proteins, which
simulates VSMC migration toward chemoattractants
released at sites of vascular injury, atherosclerosis, or
intimal hyperplasia.
Current theories about chemotaxis and cellular
signal transduction support that the signaling sys-
tems involved are G protein receptor-coupled and
protein tyrosine kinase receptor-coupled systems.1
ECM proteins have recently been linked to the acti-
vation of these pathways in certain cells. For exam-
ple, TSP-1 receptors have been directly linked to G
protein mediated chemotaxis in polymorphonuclear
leukocytes.22 Additionally, G proteins have been
shown to affect ECM-induced VSMC chemotaxis to
varying degrees, depending on the protein
involved.3 PI3K has been implicated as being a
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Fig 4. Attenuation of vascular smooth muscle cell chemo-
taxis by protein kinase C inhibition. Preincubation of vas-
cular smooth muscle cells with the protein kinase C
inhibitor GF 109203X (1 µmol/L) significantly attenuat-
ed vascular smooth muscle cell chemotaxis toward throm-
bospondin-1 (TSP-1; P < .05). The chemoattractants
TSP-1, fibronectin (Fn), and vitronectin (Vn; 20 µg/mL)
induced a significant increase in chemotaxis of uninhibit-
ed vascular smooth muscle cells in comparison with
serum-free media (SFM; P < .05). GF 109203X had no
significant effect on migration of vascular smooth muscle
cells exposed to SFM. A representative experiment is
shown. Experiments were performed in triplicate and
repeated at least three times. *P < .05, compared with
their respective uninhibited vascular smooth muscle cell
chemotaxis toward TSP-1, Fn, or Vn.
Percent reduction of thrombospondin-1-, fibronectin-,
and vitronectin-induced vascular smooth muscle cell
chemotaxis by preincubation with LY 294002 or GF
109203X; a summary of n = 3 experiments
Percent attenuation of chemotaxis
LY 294002 (100 µmol/L) GF 109203X (1 µmol/L)
TSP-1 88.5% (± 5.7%) 64.5% (± 12.1%)
Fn 84.9% (± 8.7%) 23.0% (± 6.1%)
Vn 88.1% (± 11.1%) 19.4% (± 8.8%)
TSP-1, Thrombospondin-1; Fn, fibronectin; Vn, vitronectin.
potential regulator of the binding of domains in the
G protein receptor coupled system associated with
chemotaxis.23 Thus, inhibition of PI3K may block G
protein receptor-coupled signal transduction, there-
by inhibiting chemotaxis.
Protein tyrosine kinase-coupled receptor-linked
systems are characterized by self-phosphorylation of
their tyrosine residue on ligand binding to any of a
number of receptors.1 Focal adhesion kinase (FAK),
a protein tyrosine kinase that is activated via integrin
receptors,28 can lead to activation of the signal trans-
duction protein, Ras, resulting in MAPK activation,
which has been associated with VSMC chemo-
taxis.24 The ECM proteins have been shown to be
involved in this signaling system. Our laboratory has
reported that TSP-1 stimulates activation of FAK
and ERK1/2 in VSMCs.10,25 PI3K has been shown
to be activated in association with FAK activation
and to be integral to Fn-induced cell migration.12, 26
PKC has also been shown to be involved in protein
tyrosine kinase signaling and to be necessary for
maximal integrin-mediated activation of the MAPK
pathway.13 Additionally, both PKC and PI3K have
been associated with MAPK activation, independent
of protein tyrosine kinase signal transduction.14
Potential mechanisms by which PI3K and PKC are
involved in chemotaxis are shown in Fig 5.
PI3K, a family of lipid kinases that is inactive in
quiescent cells, is rapidly activated by extracellular
signaling, translocates to the cell membrane, and
leads to intracellular signal transduction.12 PI3K
structurally consists of a p85 α or β regulatory sub-
unit and a p110 α or β catalytic subunit. The p85
subunit of PI3K has the ability to interact simulta-
neously with multiple signaling molecules, which
results in PI3K integrating the activities of multiple
pathways.26
The PI3K inhibitor LY 294002 was used to study
the role of PI3K on VSMC chemotaxis. LY 294002, a
competitive inhibitor at the ATP-binding site of PI3K,
is specific for PI3K activity, without directly inhibiting
MAPK or PKC.27 In the current study, LY 294002
inhibited TSP-1-, Fn-, and Vn-induced VSMC
chemotaxis by 85% to 89%. This inhibition of VSMC
chemotaxis by preincubation with LY 294002 sug-
gests that ECM protein-induced VSMC chemotaxis is
at least partially dependent on the PI3K pathway. The
inhibition is consistent with other studies that have
shown inhibition of VSMC chemotaxis induced by
TSP-1 or Fn.26,28 Whether LY 294002’s inhibition of
ECM-induced chemotaxis is accomplished by attenu-
ating MAPK activation by PI3K, inhibiting PI3K reg-
ulated focal adhesion disassembly and actin filament
organization, or inhibiting integrin-FAK or G protein
signal transduction is not resolved. PI3K is a pivotal
point in cellular signaling for VSMC chemotaxis.
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Fig 5. A schematic representation of the potential involvement of phosphatidylinositol 3-kinase
(PI3K) and protein kinase C (PKC) in thrombospondin-1 (TSP-1)-, fibronectin (Fn)-, and vitronectin
(Vn)-induced vascular smooth muscle cell (VSMC) chemotaxis. PI3K may serve as an important sig-
nal transducer in chemotaxis triggered by the binding of TSP-1, Fn, or Vn. PI3K may relay its signal-
ing via its interaction with G proteins, Ras, or mitogen-activated protein kinase (MAPK). PKC is like-
ly involved in signal transduction in TSP-1-induced VSMC chemotaxis, but not that of Fn or Vn.
PKC encompasses a family of serine/threonine
kinases that have multiple isoforms. The activation
of PKC involves the phosphorylation of the ATP-
binding site and translocation of PKC from the
cytosol to the cell membrane. Activation of PKC in
a variety of cell types is associated with integrin bind-
ing and a number of cellular processes including cell
migration, cytoskeletal realignment, production of
Fn, and focal adhesion formation.29,30
The PKC inhibitor used in this study, GF
109203X, acts as a specific, competitive inhibitor at
the ATP-binding site on PKC.29 It is not isoform
specific and is not associated with direct inhibition
of MAPK or PI3K. Preincubation of VSMCs with
GF 109203X was found to significantly inhibit
TSP-1-induced VSMC chemotaxis (by 65%), 
compared with the uninhibited positive control. GF
109203X did not significantly inhibit Fn- or Vn-
stimulated chemotaxis. Our results suggest that
PKC has a functional influence on TSP-1-induced
chemotaxis, but not on Fn- or Vn-induced chemo-
taxis.
Further elucidation of PKC’s involvement in
VSMC chemotaxis is necessary. The varied effects of
PKC on the activation and inhibition of cellular
activities is influenced by the specific isoform, cell
type, agonist, and/or receptor type.29 PKC’s
involvement in activating or enhancing VSMC
migration by TSP-1 may be caused by direct activa-
tion by integrin receptors, activation by Ras, or acti-
vation of MAPK. However, the PKC isoforms that
are involved in ECM-induced VSMC chemotaxis
need to be studied further.
Our results again underscore the unique involve-
ment of TSP-1 in vascular pathophysiology and
VSMC chemotaxis. The previously reported dramat-
ic rise in concentration of TSP-1 in pathophysiologic
states may be correlated with our finding that TSP-1-
induced chemotaxis is influenced by multiple enzyme
pathways. Potentially, the nonspecific influence of
TSP-1 on multiple pathways, such as PKC and
MAPK, that are not as sensitive to other ECM pro-
teins may be related to TSP-1’s presence being
reserved for acute injury and pathophysiologic states.
In summary, this study demonstrates the com-
plexity of ECM-induced VSMC chemotaxis and the
diversity of cellular signaling by showing that TSP-
1-, Fn-, and Vn-induced VSMC chemotaxis is PI3K
dependent, whereas TSP-1 differs in its increased
dependence on PKC activation, compared with that
of Fn or Vn. Further areas of study should involve
deciphering the points at which PI3K and PKC are
most important in VSMC chemotaxis induced by
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ECM proteins. As knowledge of the cell signaling
pathways involved in ECM protein-induced cell
migration of vascular cells is gained, its differential
role in the pathophysiology of vascular disease will
be better understood.
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DISCUSSION
Dr K. Craig (New York, NY) I would like to thank Drs
Willis and Gahtan for allowing me to review this manu-
script ahead of time. This was an excellent presentation.
This is research that I am very interested in, and I think it
is research that is very relevant to all of us as vascular sur-
geons. I have a couple of points and then three questions.
The first point that I would like to make is that study-
ing the processes of migration versus that of proliferation,
I think, is something that is fairly new but is of very much
importance to understanding the process of intimal hyper-
plasia. For many years, and I think in our first studies of
intimal hyperplasia, the greatest focus was on proliferation
of smooth muscle cells, but I think we have learned
recently that migration may be a more important factor
than proliferation. I acknowledge your contributions in
studying this particular process.
The second point I would like to make is that—I guess
the question to ask is—why is it relevant to vascular sur-
geons to understand signaling pathways in smooth muscle
cells? I guess I would give you my own answer, which is
that in the past we have created a number of inhibitors of
intimal hyperplasia. Most of those inhibitors work by just
being toxic to cells in general: toxic to smooth muscle
cells, endothelial cells, and all cells within an arterial wall.
I think what signaling pathways and understanding these
pathways allow us to do is design inhibitors that are very
specific to cells and specific processes in cells, so you might
find an inhibitor that can stop smooth muscle cells from
migrating but allow endothelial cells to migrate. This leads
to my questions.
The first question is, have you any knowledge of what
these inhibitors might do with endothelial cells? Are they
selective in stopping signaling pathways in smooth muscle
cells and smooth muscle cell migration, or do they likewise
alter endothelial cell migration and proliferation?
The second question has to do with some work that
we have done. We have found specifically that protein
kinase C activation inhibits smooth muscle cell migration.
Your finding is just the opposite: protein kinase C activa-
tion, in fact, stimulates migration of smooth muscle cells.
We have discussed these different findings. Is there any
insight as to why the findings in your cells might be dif-
ferent than what we found with human saphenous vein
smooth muscle cells?
In response to your question concerning endothelial
cells, our laboratory is very interested in studying migra-
tion by endothelial cells; although we have chosen to focus
on smooth muscle cells since their migration has been
demonstrated to be critically involved in the development
of intimal hyperplasia.
The last question I have is, do you have any idea of the
relevance of these three matrix proteins that you studied
to the overall process of intimal hyperplasia versus that of
other growth factors like PDGF and FGF? Did you choose
these growth factors because you felt that they were more
important in the pathophysiology of intimal hyperplasia
than say, other matrix proteins or growth factors?
Again, an excellent presentation. I very much enjoyed
it and am looking forward to your answers.
Dr Willis (New Haven, Conn). Let me actually start
with the last one and go in reverse order.
There was a reason that we selected fibronectin, throm-
bospondin, and vitronectin. We initially started studying
thrombospondin because of its presence as an acute phase
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reactant. It is virtually absent in plasma and in the normal
vessel wall and can acutely increase in concentration and inti-
mal plaques. Also, in plasma concentrations, it can increase
anywhere from 10- to 250-fold in certain disease states. That
was our initial reason for looking at thrombospondin. 
As you know, most research has been done in the area
of PDGF looking at growth factors, and we thought that it
would be interesting to look at other extracellular matrix
proteins. In looking around at people who were looking at
other extracellular matrix proteins, including yourself, you
were looking at fibronectin in particular, which caused us to
look at fibronectin and vitronectin. In the future we would
like to look at some other extracellular matrix proteins.
Those two proteins are normally present in the vessel wall,
and we thought that would be a good point to start with in
terms of examining an acute phase reactant extracellular
protein versus some that are normally present in the wall.
In terms of the protein kinase C activation, that is actu-
ally a very interesting area, because as I mentioned, there
are multiple isoforms. At this point about 11 different iso-
forms of protein kinase C are known. There are multiple
different inhibitors of protein kinase C. They can inhibit
different isoforms. What we have selected as our inhibitor
is the GF inhibitor. That is an isoform nonspecific inhibitor.
It inhibits the ATP-binding site, and we wanted to start
looking at the role of protein kinase C by looking at a rel-
atively nonspecific inhibitor. That inhibitor has been
reviewed in other studies—one by Dr Kent—in terms of its
effect on production of fibronectin, but really not on the
vascular smooth muscle cells’ ability to migrate. That is
what we wanted to look at, and in the future as we look at
different isoforms, we may be able to better pinpoint exact-
ly how isoform is affecting migration versus proliferation or
production of other extracellular matrix proteins.
In response to your question concerning endothelial
cells, our laboratory is very interested in studying migra-
tion by endothelial cells; although, we have chosen to focus
on smooth muscle cells since their migration has been
demonstrated to be critically involved in the development
of intimal hyperplasia.
Don’t miss a single issue of the journal!  To ensure prompt service when you change your address,
please photocopy and complete the form below. 
Please send your change of address notification at least six weeks before your move to ensure continued ser-
vice.  We regret we cannot guarantee replacement of issues missed due to late notification.
JOURNAL TITLE:
Fill in the title of the journal here.
OLD ADDRESS:
Affix the address label from a recent issue of the journal here. NEW ADDRESS:




Send us your new address at least six weeks aheadO N THE MOVE?
COPY AND MAIL THIS FORM TO: OR FAX TO: OR PHONE:
Mosby 407-363-9661 800-654-2452
Subscription Customer Service Outside the US, call
6277 Sea Harbor Dr 407-345-4000
Orlando, FL, 32887
